Chinese biotech firm BGI sees booming revenue, profits in first 3 quarters

BEIJING, Nov. 1 (Xinhua) -- Chinese biotech company BGI Genomics Co., Ltd. registered robust growth in its revenue and profits in the first three quarters on the back of rocketing demand for diagnostic kits.

The company reported 2.71 billion yuan (about 403 million U.S. dollars) in net profits for its parent company in the first nine months, soaring 901.68 percent year on year, according to its report filed with the Shenzhen Stock Exchange.

During the period, the firm raked in 6.75 billion yuan in operating revenue, up 225.82 percent year on year, said the report.

The enterprise attributed the growth to surging demand for diagnostic kits and detection services due to the COVID-19 epidemic, which has spurred its business in the fields of infection prevention and control and comprehensive solutions for precision medicine, the report said.

BGI provides services in areas including reproductive health, cancer prevention and control, pathogenic infection and precision medicine.

北京，11月1日(新华社)——中国生物技术公司华大基因有限公司在前三季度收入和利润增长强劲，主要得益于对诊断试剂盒的快速需求。

根据提交给深圳证券交易所的报告，该公司报告称，在前九个月，其母公司的净利润为27.1亿元(约合4.03亿美元)，同比增长901.68%。

该报告称，在此期间，该公司的营业收入为67.5亿元，同比增长225.82%。

报告称，该企业将增长归因于COVID-19疫情对诊断试剂盒和检测服务的需求激增，这刺激了其在感染防控和精准医疗综合解决方案领域的业务。

华大基因在生殖健康、癌症防控、致病性感染和精准医疗等领域提供服务。